The evolution towards ambulatory and day-case management of febrile neutropenia

British Journal of Haematology

Volumn 135, Issue 1, 2006, Pages 3-16

  Chisholm, Julia C ^a   Dommett, Rachel ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Ambulatory; Day case; Febrile neutropenia; Low risk; Outpatient

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; VANCOMYCIN;

AMBULATORY CARE; CLINICAL TRIAL; DRUG TOXICITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SYSTEMATIC REVIEW;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; FEVER; HUMANS; NEUTROPENIA; PATIENT SELECTION; RISK ASSESSMENT;

EID: 33748347079     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06253.x     Document Type: Review

References (94)

1. Alexander, S.W., Wade, K.C., Hibberd, P.L. & Parsons, S.K. (2002) Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. Journal of Pediatric Hematology and Oncology, 24, 28-42.
2. Ammann, R.A., Hirt, A., Luthy, A.R. & Aebi, C. (2003) Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Medical and Pediatric Oncology, 41, 436-443.
3. Ammann, R.A., Simon, A. & de Bont, E.S. (2005) Low risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care? Pediatric Blood and Cancer, 45, 244-247.
4. Aquino, V.M., Tkaczewski, I. & Buchanan, G.R. (1997) Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clinical Infectious Diseases, 25, 74-78.
5. Aquino, V.M., Herrera, L., Sandler, E.S. & Buchanan, G.R. (2000) Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer, 88, 1710-1714.
6. Armstrong, D., Young, L.S., Meyer, R.D. & Blevins, A.H. (1971) Infectious complications of neoplastic disease. Medical Clinics of North America, 55, 729-745.
7. Baorto, E.P., Aquino, V.M., Mullen, C.A., Buchanan, G.R. & DeBaun, M.R. (2001) Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer, 92, 909-913.
8. Barza, M., Ioannidis, J.P., Cappelleri, J.C. & Lau, J. (1996) Single or multiple daily doses of aminoglycosides: a meta-analysis. British Medical Journal, 312, 338-345.
9. Bash, R.O., Katz, J.A., Cash, J.V. & Buchanan, G.R. (1994) Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer, 74, 189-196.
10. Basu, S.K., Fernandez, I.D., Fisher, S.G., Asselin, B.L. & Lyman, G.H. (2005) Length of stay and mortality associated with febrile neutropenia among children with cancer. Journal of Clinical Oncology, 23, 7958-7966.
11. de Bont, E.S., Vellenga, E., Swaanenburg, J.C., Fidler, V., Visser-van Brummen, P.J. & Kamps, W.A. (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. British Journal of Haematology, 107, 375-380.
12. Bouffet, E., Fuhrmann, C., Frappaz, D., Couillioud, D., Artiges, V., Charra, C., Bouhour, D. & Brunat, M.M. (1994) Once daily antibiotic regimen in paediatric oncology. Archives of Diseases in Childhood, 70, 484-487.
13. Chamilos, G., Bamias, A., Efstathiou, E., Zorzou, P.M., Kastritis, E., Kostis, E., Papadimitriou, C. & Dimopoulos, M.A. (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer, 103, 2629-2635.
14. Cherif, H., Johansson, E., Bjorkholm, M. & Kalin, M. (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica, 91, 215-222.
15. Dommett, R., Sharland, M., Freeman, S., Vaidya, S., Davidson, A., Tulloh, R., Stoneham, S., Taj, M., Daw, S., Hartley, J. & Chisholm, J. (2005) Prospective audit of a low risk management strategy in febrile neutropenia (FN) - a Thames Paediatric Oncology Centre (TPOC) study. Pediatric Blood and Cancer, 45, 418.
16. Elting, L.S., Rubenstein, E.B., Rolston, K.V. & Bodey, G.P. (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clinical Infectious Diseases, 25, 247-259.
17. Escalante, C.P., Weiser, M.A., Manzullo, E., Benjamin, R., Rivera, E., Lam, T., Ho, V., Valdres, R., Lee, E.L., Badrina, N., Fernandez, S., DeJesus, Y. & Rolston, K. (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Supportive Care in Cancer, 12, 657-662.
18. Feld, R., Paesmans, M., Freifeld, A.G., Klastersky, J., Pizzo, P.A., Rolston, K.V., Rubenstein, E., Talcott, J.A. & Walsh, T.J. (2002) Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical Infectious Diseases, 35, 1463-1468.
19. Flaherty, J.P., Waitley, D., Edlin, B., George, D., Arnow, P., O'Keefe, P. & Weinstein, R.A. (1989) Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. American Journal of Medicine, 87, 278S-282S.
20. Freifeld, A., Marchigiani, D., Walsh, T., Chanock, S., Lewis, L., Hiemenz, J., Hiemenz, S., Hicks, J.E., Gill, V., Steinberg, S.M. & Pizzo, P.A. (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine, 341, 305-311.
21. Gardembas-Pain, M., Desablens, B., Sensebe, L., Lamy, T., Ghandour, C. & Boasson, M. (1991) Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Annals of Oncology, 2, 485-487.
22. Giamarellou, H., Bassaris, H.P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E. & Zoumbos, N. (2000) Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy, 44, 3264-3271.
23. Grady, R. (2003) Safety profile of quinolone antibiotics in the pediatric population. The Pediatric Infectious Disease Journal, 22, 1128-1132.
24. Hann, I., Viscoli, C., Paesmans, M., Gaya, H. & Glauser, M. (1997) A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). British Journal of Haematology, 99, 580-588.
25. Hatala, R., Dinh, T.T. & Cook, D.J. (1997) Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clinical Infectious Diseases, 24, 810-815.
26. Hidalgo, M., Hornedo, J., Lumbreras, C., Trigo, J.M., Colomer, R., Perea, S., Gomez, C., Ruiz, A., Garcia-Carbonero, R. & Cortes-Funes, H. (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer, 85, 213-219.
27. Hodge, G., Osborn, M., Hodge, S., Nairn, J., Tapp, H., Kirby, M., Sepulveda, H., Morgan, E., Revesz, T. & Zola, H. (2006) Rapid simultaneous measurement of multiple cytokines in childhood oncology patients with febrile neutropenia: increased interleukin (IL)-8 or IL-5 correlates with culture-positive infection. British Journal of Haematology, 132, 247-248.
28. Hughes, W.T., Armstrong, D., Bodey, G.P., Feld, R., Mandell, G.L., Meyers, J.D., Pizzo, P.A., Schimpff, S.C., Shenep, J.L., Wade, J.C., Young, L.S., Yow, M.D. (1990) From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases, 161, 381-396.
29. Innes, H.E., Smith, D.B., O'Reilly, S.M., Clark, P.I., Kelly, V. & Marshall, E. (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer, 89, 43-49.
30. Innes, H., Billingham, L., Gaunt, C., Steven, N. & Marshall, E. (2005) Management of febrile neutropenia in the United Kingdom: time for a national trial? British Journal of Cancer, 93, 1324-1328.
31. Johansson, E., Bjorkholm, M., Wredling, R., Kalin, M. & Engervall, P. (2001) Outpatient parenteral antibiotic therapy in patients with haematological malignancies. A pilot study of an early discharge strategy. Supportive Care in Cancer, 9, 619-624.
32. Jones, G.R., Konsler, G.K., Dunaway, R.P., Gold, S.H., Cooper, H.A. & Wells, R.J. (1994) Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. Journal of Pediatrics, 124, 703-708.
33. Kaplinsky, C., Drucker, M., Goshen, J., Tamary, H., Cohen, I.J. & Zaizov, R. (1994) Ambulatory treatment with ceftriaxone in febrile neutropenic children. Israeli Journal of Medical Sciences, 30, 649-651.
34. Karthaus, M., Egerer, G., Kullmann, K.H., Ritter, J. & Jurgens, H. (1998) Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. European Journal of Clinical Microbiology and Infectious Diseases, 17, 501-504.
35. Kern, W.V., Cometta, A., De Bock, R., Langenaeken, J., Paesmans, M. & Gaya, H. (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine, 341, 312-318.
36. Klaassen, R.J., Allen, U. & Doyle, J.J. (2000a) Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. Journal of Pediatric Hematology and Oncology, 22, 405-411.
37. Klaassen, R.J., Goodman, T.R., Pham, B. & Doyle, J.J. (2000b) 'Low-risk' prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology, 18, 1012-1019.
38. Klastersky, J., Paesmans, M., Rubenstein, E.B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K. & Talcott, J. (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
39. Kuderer, N.M., Dale, D.C., Crawford, J., Cosler, L.E. & Lyman, G.H. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-2266.
40. Lau, R.C., Doyle, J.J., Freedman, M.H., King, S.M. & Richardson, S.E. (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatric Hematology and Oncology, 11, 417-421.
41. Lehrnbecher, T., Venzon, D., de Haas, M., Chanock, S.J. & Kuhl, J. (1999) Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clinical Infectious Diseases, 29, 414-419.
42. Lehrnbecher, T., Fleischhack, G., Hanisch, M., Deinlein, F., Simon, A., Bernig, T., Chanock, S.J. & Klingebiel, T. (2004) Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Haematologica, 89, 234-236.
43. Lilienfeld-Toal, M., Dietrich, M.P., Glasmacher, A., Lehmann, L., Breig, P., Hahn, C., Schmidt-Wolf, I.G., Marklein, G., Schroeder, S. & Stuber, F. (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. European Journal of Clinical Microbiology and Infectious Diseases, 23, 539-544.
44. Lucas, K.G., Brown, A.E., Armstrong, D., Chapman, D. & Heller, G. (1996) The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer, 77, 791-798.
45. Madsen, K., Rosenman, M., Hui, S. & Breitfeld, P.P. (2002) Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. Journal of Pediatric Hematology and Oncology, 24, 256-262.
46. Malik, I.A. (1997) Out-patient management of febrile neutropenia in indigent paediatric patients. Annals of the Academy of Medicine, Singapore, 26, 742-746.
47. Malik, I.A., Abbas, Z. & Karim, M. (1992) Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet, 339, 1092-1096.
48. Malik, I.A., Khan, W.A., Aziz, Z. & Karim, M. (1994) Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Diseases, 19, 522-527.
49. Malik, I.A., Khan, W.A., Karim, M., Aziz, Z. & Khan, M.A. (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. American Journal of Medicine, 98, 224-231.
50. Martino, P., Girmenia, C., Raccah, R., Micozzi, A., Cimino, G., Sgadari, C. & Gentile, G. (1992) Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology, 49, 49-52.
51. Minotti, V., Gentile, G., Bucaneve, G., Iori, A.P., Micozzi, A., Cavicchi, F., Barbabietola, G., Landonio, G., Menichetti, F., Martino, P. & Del Favero, A. (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer, 7, 134-139.
52. Mullen, C.A. (2001) Which children with fever and neutropenia can be safely treated as outpatients? British Journal of Haematology, 112, 832-837.
53. Mullen, C.A., Petropoulos, D., Roberts, W.M., Rytting, M., Zipf, T., Chan, K.W., Culbert, S.J., Danielson, M., Jeha, S.S., Kuttesch, J.F. & Rolston, K.V. (1999a) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer, 86, 126-134.
54. Mullen, C.A., Petropoulos, D., Roberts, W.M., Rytting, M., Zipf, T., Chan, K.W., Culbert, S.J., Danielson, M., Jeha, S.S., Kuttesch, J.F. & Rolston, K.V. (1999b) Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. Journal of Pediatric Hematology and Oncology, 21, 212-218.
55. Mustafa, M.M., Aquino, V.M., Pappo, A., Tkaczewski, I. & Buchanan, G.R. (1996) A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics, 128, 847-849.
56. Neth, O., Hann, I., Turner, M.W. & Klein, N.J. (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet, 358, 614-618.
57. Nijhuis, C.O., Kamps, W.A., Daenen, S.M., Gietema, J.A., van der Graaf, W.T., Groen, H.J., Vellenga, E., Ten Vergert, E.M., Vermeulen, K.M., Vries-Hospers, H.G. & de Bont, E.S. (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. Journal of Clinical Oncology, 23, 7437-7444.
58. Orudjev, E. & Lange, B.J. (2002) Evolving concepts of management of febrile neutropenia in children with cancer. Medical and Pediatric Oncology, 39, 77-85.
59. Oude Nijhuis, C.S., Daenen, S.M., Vellenga, E., van der Graaf, W.T., Gietema, J.A., Groen, H.J., Kamps, W.A. & de Bont, E.S. (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Critical Reviews in Oncology/Hematology, 44, 163-174.
60. Paganini, H.R., Sarkis, C.M., De Martino, M.G., Zubizarreta, P.A., Casimir, L., Fernandez, C., Armada, A.A., Rodriguez-Brieshcke, M.T. & Debbag, R. (2000) Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer, 88, 2848-2852.
61. Paganini, H., Rodriguez-Brieshcke, T., Zubizarreta, P., Latella, A., Firpo, V., Casimir, L., Armada, A., Fernandez, C., Caceres, E. & Debbag, R. (2001) Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer, 91, 1563-1567.
62. Paganini, H., Gomez, S., Ruvinsky, S., Zubizarreta, P., Latella, A., Fraquelli, L., Iturres, A.S., Casimir, L. & Debbag, R. (2003) Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer, 97, 1775-1780.
63. Papadimitris, C., Dimopoulos, M.A., Kostis, E., Papadimitriou, C., Anagnostopoulos, A., Alexopoulos, G., Papamichael, C., Gika, D., Mitsibounas, D. & Stamatelopoulos, S. (1999) Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology, 57, 127-130.
64. Park, J.R., Coughlin, J., Hawkins, D., Friedman, D.L., Burns, J.L. & Pendergrass, T. (2003) Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Medical and Pediatric Oncology, 40, 93-98.
65. Paul, M., Soares-Weiser, K. & Leibovici, L. (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. British Medical Journal, 326, 1111.
66. Paul, M., Yahav, D., Fraser, A. & Leibovici, L. (2006) Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 57, 176-189.
67. Persson, L., Soderquist, B., Engervall, P., Vikerfors, T., Hansson, L.O. & Tidefelt, U. (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. European Journal of Haematology, 74, 297-303.
68. Pession, A., Prete, A. & Paolucci, G. (1997) Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. Chemotherapy, 43, 358-366.
69. Petrilli, A.S., Dantas, L.S., Campos, M.C., Tanaka, C., Ginani, V.C. & Seber, A. (2000) Oral ciprofloxacin versus intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology, 34, 87-91.
70. Pizzo, P.A., Robichaud, K.J., Gill, F.A., Witebsky, F.G., Levine, A.S., Deisseroth, A.B., Glaubiger, D.L., MacLowry, J.D., Magrath, I.T., Poplack, D.G. & Simon, R.M. (1979) Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. American Journal of Medicine, 67, 194-200.
71. Preis, S., Jurgens, H., Friedland, C., Oudekotte-David, A.A., Thomas, L. & Gobel, U. (1993) Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klinische Padiatrie, 205, 295-299.
72. Quezada, G., Sunderland, T., Chan, K.W., Rolston, K. & Mullen, C.A. (2006) Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatric Blood and Cancer, doi 10.1002/pbc.20774.
73. Rackoff, W.R., Gonin, R., Robinson, C., Kreissman, S.G. & Breitfeld, P.B. (1996) Predicting the risk of bacteremia in children with fever and neutropenia. Journal of Clinical Oncology, 14, 919-924.
74. Raisch, D.W., Holdsworth, M.T., Winter, S.S., Hutter, J.J. & Graham, M.L. (2003) Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children. Value in Health, 6, 158-166.
75. Rapoport, B.L., Sussmann, O., Herrera, M.V., Schlaeffer, F., Otero, J.C., Pavlovsky, S., Iglesias, L., Stein, G., Charnas, R., Heitlinger, E. & Handschin, J. (1999) Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge versus Standard In-patient care. Chemotherapy, 45, 466-476.
76. Rubenstein, E.B., Rolston, K., Benjamin, R.S., Loewy, J., Escalante, C., Manzullo, E., Hughes, P., Moreland, B., Fender, A., Kennedy, K., Holmes, F., Elting, L., Bodey, G.P. (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer, 71, 3640-3646.
77. Sahu, S., Bapna, A., Pai, S.K., Nair, C.N., Kurkure, P.A. & Advani, S.H. (1997) Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatric Hematology and Oncology, 14, 205-211.
78. Santolaya, M.E., Alvarez, A.M., Becker, A., Cofre, J., Enriquez, N., O'Ryan, M., Paya, E., Pilorget, J., Salgado, C., Tordecilla, J., Varas, M., Villarroel, M., Viviani, T. & Zubieta, M. (2001) Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. Journal of Clinical Oncology, 19, 3415-3421.
79. Santolaya, M.E., Alvarez, A.M., Aviles, C.L., Becker, A., Cofre, J., Enriquez, N., O'Ryan, M., Paya, E., Salgado, C., Silva, P., Tordecilla, J., Varas, M., Villarroel, M., Viviani, T. & Zubieta, M. (2002) Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases, 35, 678-683.
80. Santolaya, M.E., Alvarez, A.M., Aviles, C.L., Becker, A., Cofre, J., Cumsille, M.A., O'Ryan, M.L., Paya, E., Salgado, C., Silva, P., Tordecilla, J., Varas, M., Villarroel, M., Viviani, T. & Zubieta, M. (2004) Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology, 22, 3784-3789.
81. Schimpff, S., Satterlee, W., Young, V.M. & Serpick, A. (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine, 284, 1061-1065.
82. Shemesh, E., Yaniv, I., Drucker, M., Hadad, S., Goshen, Y., Stein, J., Ash, S., Fisher, S. & Zaizov, R. (1998) Home intravenous antibiotic treatment for febrile episodes in immune-compromised pediatric patients. Medical and Pediatric Oncology, 30, 95-100.
83. Shenep, J.L., Flynn, P.M., Baker, D.K., Hetherington, S.V., Hudson, M.M., Hughes, W.T., Patrick, C.C., Roberson, P.K., Sandlund, J.T., Santana, V.M., Sixbey, J.W. & Slobod, K.S. (2001) Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Diseases, 32, 36-43.
84. Sipsas, N.V., Bodey, G.P. & Kontoyiannis, D.P. (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer, 103, 1103-1113.
85. Sung, L., Feldman, B.M., Schwamborn, G., Paczesny, D., Cochrane, A., Greenberg, M.L., Maloney, A.M., Hendershot, E.I., Naqvi, A., Barrera, M. & Llewellyn-Thomas, H.A. (2004) Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. Journal of Clinical Oncology, 22, 3922-3929.
86. Talcott, J.A., Finberg, R., Mayer, R.J. & Goldman, L. (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Archives of Internal Medicine, 148, 2561-2568.
87. Talcott, J.A., Siegel, R.D., Finberg, R. & Goldman, L. (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology, 10, 316-322.
88. Talcott, J.A., Whalen, A., Clark, J., Rieker, P.P. & Finberg, R. (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology, 12, 107-114.
89. Uys, A., Rapoport, B.L. & Anderson, R. (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Supportive Care in Cancer, 12, 555-560.
90. Vallejo, C., Caballero, M.D., Garcia-Sanz, R., Hernandez, J.M., Vazquez, L., Canizo, M.C., Galende, J., Colino, C.I., Gil-Hurle, A. & San Miguel, J.F. (1997) Sequential intravenous-oral ciprofloxacin plus amoxycillin/ clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology and Cell Therapy, 39, 223-227.
91. Velasco, E., Costa, M.A., Martins, C.A. & Nucci, M. (1995) Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology, 18, 429-435.
92. Vidal, L., Paul, M., Ben, D.I., Soares-Weiser, K. & Leibovici, L. (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. Journal of Antimicrobial Chemotherapy, 54, 29-37.
93. Wacker, P., Halperin, D.S., Wyss, M. & Humbert, J. (1997) Early hospital discharge of children with fever and neutropenia: a prospective study. Journal of Pediatric Hematology and Oncology, 19, 208-211.
94. Wiernikowski, J.T., Rothney, M., Dawson, S. & Andrew, M. (1991) Evaluation of a home intravenous antibiotic program in pediatric oncology. American Journal of Pediatric Hematology and Oncology, 13, 144-147.